Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 7/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 15/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5792445 | 0.77 | CYP19A1 (0.47) | CYP11B2CYP19A1CYP11B1KCNH2 | |
| SCHEMBL2350719 | 0.67 | CYP19A1 (0.69) | CYP11B2CYP19A1CYP11B1KCNH2 | |
| SCHEMBL14585840 | 0.66 | CYP19A1 (0.55) | CYP11B2CYP19A1CYP11B1KCNH2 | |
| SCHEMBL12459330 | 0.66 | CYP19A1 (0.51) | CYP11B2CYP19A1CYP11B1KCNH2 | |
| SCHEMBL27283098 | 0.66 | CYP19A1 (0.55) | CYP11B2CYP19A1CYP11B1KCNH2 | |
| SCHEMBL8985190 | 0.65 | NOTUM (0.36) | CYP11B2CYP19A1 | |
| Hydrochloric Acid SCHEMBL8985242 | 0.64 | NOTUM (0.35) | CYP11B2CYP19A1 | |
| SCHEMBL11947581 | 0.62 | L3MBTL3 (0.53) | — | |
| SCHEMBL30915762 | 0.62 | KDM4E (0.39) | — | |
| SCHEMBL17317666 | 0.62 | KDM4E (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2261225-A1 | Heterocyclic compounds and their use as aldosterone synthase inhibitors | Novartis AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| US-20100029694-A1 | Heterocyclic compounds and their use as aldosterone synthase inhibitors | HEROLD PETER | 2010-02-04 | — | — | US | disclosed |
| US-7612088-B2 | Heterocyclic compounds and their use as aldosterone synthase inhibitors | SPEEDEL EXPERIMENTA AG (CH) | 2009-11-03 | — | — | US | disclosed |
| US-20080318978-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ALDOSTERONE SYNTHASE INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20070208035-A1 | Heterocyclic compounds and their use as aldosterone synthase inhibitors | HONDA MOTOR CO., LTD. (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1749006-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ALDOSTERONE SYNTHASE INHIBITORS | Speedel Experimenta AG (CH) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005118557-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ALDOSTERONE SYNTHASE INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318978-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ALDOSTERONE SYNTHASE INHIBITORS | CYP11B1, CYP11B2, CYP21A2 | CYP11B2 2/4885CYP19A1 41/4885CYP11B1 1/4885 |
| US-20100029694-A1 | Heterocyclic compounds and their use as aldosterone synthase inhibitors | CYP11B1, CYP11B2, CYP21A2 | CYP11B2 2/4885CYP19A1 36/4885CYP11B1 1/4885 |
| US-20070208035-A1 | Heterocyclic compounds and their use as aldosterone synthase inhibitors | CYP11B1, CYP11B2, CYP21A2 | CYP11B2 2/4885CYP19A1 41/4885CYP11B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.